全球不孕症治疗市场规模、份额、趋势和成长分析报告（2026-2034）

预计不孕症治疗市场将从 2025 年的 43.6 亿美元成长到 2034 年的 75.8 亿美元，2026 年至 2034 年的复合年增长率为 6.34%。

随着全球不孕症的上升，全球不孕症治疗药物市场正经历显着成长。生活方式的改变、受孕延迟以及生殖健康问题的增加是导致男性和女性不孕症的主要因素。不孕症治疗药物广泛应用于辅助生殖技术中，以促进排卵并提高怀孕成功率。

生殖医学的进步和人们对不孕症治疗认识的提高正在推动对不孕症药物的需求。医疗机构提供多种药物疗法，包括荷尔蒙疗法和促排卵药物，作为不孕症治疗方案的一部分。此外，不孕症诊所的扩张和辅助生殖技术普及程度的提高也促进了市场成长。

展望未来，随着生殖医学研究的不断深入，全球不孕症治疗市场预计将持续成长。製药公司正在研发创新药物，以提高治疗效果并减少副作用。随着人们对不孕症治疗的健康意识不断提高以及治疗服务的不断扩展，不孕症治疗市场预计将保持持续成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球不孕症治疗市场：依药物类别划分

• 市场分析、洞察与预测
• 促性腺激素分泌
• Aromatase抑制剂
• 选择性雌激素受体调节（SERMs）
• 多巴胺促效剂
• 其他的

第五章：全球不孕症药物市场：依分销管道划分

• 市场分析、洞察与预测
• 医院药房
• 专科药房和零售药房
• 网路药房

第六章：全球不孕症药物市场：依最终用户划分

• 市场分析、洞察与预测
• 男性
• 女士

第七章 全球不孕症治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Merck & Co. Inc
  • Ferring BV
  • Organon Group Of Companies
  • Abbott
  • Novartis AG
  • Bayer AG
  • Pfizer Inc
  • Mankind Pharma
  • Teva Pharmaceutical Industries LTD
  • Sanofi

The Infertility Drugs Market size is expected to reach USD 7.58 Billion in 2034 from USD 4.36 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.

The Global Infertility Drugs Market is witnessing significant growth as infertility rates continue to rise worldwide. Lifestyle changes, delayed pregnancies, and increasing prevalence of reproductive health disorders are major factors contributing to infertility among both men and women. Infertility drugs are widely used in assisted reproductive treatments to stimulate ovulation and improve the chances of successful conception.

Advancements in reproductive medicine and increasing awareness about fertility treatments are driving demand for infertility drugs. Healthcare providers are offering a wide range of pharmaceutical treatments as part of fertility therapy programs, including hormone therapies and ovulation induction medications. In addition, the expansion of fertility clinics and improved access to assisted reproductive technologies are supporting market growth.

Looking ahead, the Global Infertility Drugs Market is expected to grow as research in reproductive medicine continues to advance. Pharmaceutical companies are developing innovative drug formulations that improve treatment outcomes and reduce side effects. With increasing awareness about fertility health and expanding fertility treatment services, the market for infertility drugs is projected to experience sustained growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Gonadotropins
• Aromatase Inhibitors
• Selective Estrogen Receptor Modulators (SERMs)
• Dopamine Agonists
• Others

By Distribution Channel

• Hospital Pharmacy
• Specialty & Retail Pharmacy
• Online Pharmacy

By End-user

• Men
• Women

COMPANIES PROFILED

• Merck Co Inc, Ferring BV, Organon Group of Companies, Abbott, Novartis AG, Bayer AG, Pfizer Inc, Mankind Pharma, Teva Pharmaceutical Industries LTD, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INFERTILITY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Gonadotropins Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aromatase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Selective Estrogen Receptor Modulators (SERMs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Dopamine Agonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INFERTILITY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Specialty & Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INFERTILITY DRUGS MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Men Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Women Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INFERTILITY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Distribution Channel
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Distribution Channel
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Distribution Channel
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Distribution Channel
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Distribution Channel
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL INFERTILITY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Merck & Co. Inc
  • 9.2.2 Ferring B.V
  • 9.2.3 Organon Group Of Companies
  • 9.2.4 Abbott
  • 9.2.5 Novartis AG
  • 9.2.6 Bayer AG
  • 9.2.7 Pfizer Inc
  • 9.2.8 Mankind Pharma
  • 9.2.9 Teva Pharmaceutical Industries LTD
  • 9.2.10 Sanofi